胃滞留给药系统 (GRDDS) 外包市场报告：2030 年趋势、预测与竞争分析

胃滞留给药系统（GRDDS）外包趋势与预测

全球胃滞留给药系统（GRDDS）外包市场前景广阔，高密度系统、可扩展给药系统、生物黏附给药系统和浮动给药系统市场都有机会。预计2024年至2030年全球胃留置给药系统外包市场将以6.7%的复合年增长率成长。该市场的主要驱动力是越来越重视以患者为中心的解决方案、不断增长的外包需求、越来越关注局部药物输送以及增加对研发项目的投资。

• Lucintel 预测，以剂型划分，胶囊将在预测期内达到最高成长。
• 从市场类型来看，浮动给药系统预计将成长最快。
• 从地区来看，由于其成熟的製药业、强大的研发能力、强劲的市场需求和完善的医疗保健体系，预计北美在预测期内将出现最高的成长。

胃滞留给药系统（GRDDS）外包市场的策略性成长机会

随着製药公司越来越注重开发针对慢性和复杂疾病的先进药物输送系统，胃滞留药物输送系统（GRDDS）外包市场提供了重要的策略性成长机会。外包的好处，例如降低成本、加快产品开发速度以及获得专业知识，为市场成长创造了有利的环境。透过利用这些机会，受託製造厂商(CMO) 可以扩展其能力、增强其服务产品并开拓新市场。

• 扩大外包伙伴关係：製药公司越来越多地与专门从事 GRDDS 的 CMO 合作，以简化生产流程、提高效率并获得最尖端科技。
• 对慢性病管理的需求不断增加：糖尿病、高血压和胃肠道疾病等慢性病的增加为开发旨在提高长期用药依从性的专门 GRDDS 製剂提供了机会。
• 地理扩张：将外包业务扩展到医疗保健需求不断增长的新兴市场，为首席行销长提供了在新地区获得市场占有率的重大机会。
• 个人化医疗：个人化、针对患者的配方的趋势为 GRDDS 公司提供了巨大的机会，可以根据个人治疗需求提供量身定制的解决方案。
• 先进技术整合：将人工智慧、资料分析等先进技术整合到GRDDS的外包流程中，可优化产品开发、降低成本并提高品管。

在对专业药物输送系统的需求、慢性病管理的进步以及对个性化医疗的需求的推动下，胃滞留药物输送系统（GRDDS）外包市场存在大量战略增长机会。 CMO 可以透过专注于扩大外包伙伴关係关係、扩大地理覆盖范围和整合下一代技术来利用这些机会。随着市场的成长，这些因素可能塑造胃滞留给药系统（GRDDS）外包的未来，并开闢新的成长途径。

胃滞留给药系统（GRDDS）外包市场推广因素与挑战

胃滞留药物输送系统（GRDDS）外包市场受到各种驱动因素​​的影响，例如对先进药物输送技术的需求不断增长、慢性病管理的医疗保健需求不断增长以及我所收到的具有成本效益的药物製造趋势。然而，它们也面临一些挑战，包括监管复杂性、高製造成本和技术限制。对于希望驾驭竞争格局并利用成长机会的公司来说，了解这些驱动因素和挑战至关重要。

市场驱动因素

• 慢性病治疗需求不断增加：糖尿病和高血压等慢性病的增加增加了对可控和持续药物释放的需求，从而创造了对 GRDDS 的需求。
• 外包以降低成本：製药公司越来越多地外包 GRDDS 製造，以降低製造成本、提高业务灵活性并加快上市时间。
• 製剂技术的进步：生物黏附系统和控制释放机制等药物传递技术的不断改进正在支持GRDDS应用的成长。
• 强调用药依从性：GRDDS在提高病患长期治疗顺从性方面发挥重要作用，促进GRDDS在慢性病管理的应用。
• 收紧监管以实现更安全、更有效的治疗方法：收紧给药系统的监管要求正在推动创新，并不断增加对可靠、合规的 GRDDS 解决方案的需求。

市场挑战

• 高开发和製造成本：开发和製造GRDDS配方的复杂性可能会导致高昂的初始投资和营运成本，特别是对于中小型企业而言。
• 监管障碍：克服复杂且特定于地区的监管要求可能会延迟市场进入并增加开发成本。
• 技术复杂性：GRDDS的设计和製造需要先进的技术和专业知识，这可能会限制缺乏经验的公司进入市场。

胃滞留给药系统（GRDDS）外包市场是由慢性病治疗需求增加、技术进步和外包的成本节约效益等因素所推动的。但它们也面临开发成本高、监管复杂、技术障碍等挑战。透过克服这些挑战并利用市场驱动因素和挑战，胃滞留药物输送系统 (GRDDS) 外包领域的公司可以在快速发展的市场中实现持续成长和成功。

目录

第一章执行摘要

第二章全球胃滞留给药系统（GRDDS）外包市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球胃滞留给药系统（GRDDS）外包市场趋势（2018-2023）与预测（2024-2030）
• 依类型：全球胃滞留给药系统（GRDDS）外包市场
  • 高密度系统
  • 可扩展的药物传输系统
  • 生物黏附药物传输系统
  • 漂浮给药系统
  • 其他的
• 按剂型分類的全球胃滞留给药系统（GRDDS）外包市场
  • 药片
  • 液体
  • 微球
  • 胶囊
  • 其他的
• 依分销管道划分：全球胃滞留给药系统（GRDDS）外包市场
  • 医院药房
  • 零售药房
  • 网路药房

第四章 2018-2030年区域市场趋势及预测分析

• 按地区分類的胃滞留给药系统（GRDDS）外包市场
• 北美胃滞留给药系统（GRDDS）外包市场
• 欧洲胃滞留给药系统（GRDDS）外包市场
• 亚太胃滞留给药系统（GRDDS）外包市场
• 其他地区胃滞留给药系统（GRDDS）外包市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 按类型：全球胃滞留给药系统（GRDDS）外包市场成长机会
  • 按剂型分類的全球胃滞留给药系统 (GRDDS) 外包市场的成长机会
  • 依分销管道划分：全球胃滞留给药系统（GRDDS）外包市场的成长机会
  • 按地区划分：全球胃滞留给药系统（GRDDS）外包市场的成长机会
• 全球胃滞留给药系统（GRDDS）外包市场新趋势
• 战略分析
  • 新产品开发
  • 扩大全球胃滞留给药系统（GRDDS）外包市场的产能
  • 全球胃滞留给药系统（GRDDS）外包市场的併购与合资
  • 认证和许可

第七章主要企业概况

• F. Hoffmann La Roche
• Glaxo Smith Kline
• Lupin
• Pfizer
• Sun Pharma
• Ranbaxy
• Depomed

Gastroretentive Drug Delivery System Outsourcing Trends and Forecast

The future of the global gastroretentive drug delivery system outsourcing market looks promising with opportunities in the high-density system, expandable drug delivery system, bioadhesive drug delivery system, and floating drug delivery system markets. The global gastroretentive drug delivery system outsourcing market is expected to grow with a CAGR of 6.7% from 2024 to 2030. The major drivers for this market are increasing emphasis on patient-centric solutions, rising demand for outsourcing, a growing focus on localized drug delivery, and increasing investments in R&D programs.

• Lucintel forecasts that, within the dosage form category, the capsule is expected to witness the highest growth over the forecast period.
• Within this market, within the type category, the floating drug delivery system is expected to witness the highest growth.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to the region's sophisticated pharmaceutical sector, potent R&D capacities, robust market demand, and well-established healthcare system.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Gastroretentive Drug Delivery System Outsourcing Market

The gastroretentive drug delivery system (GRDDS) market is undergoing significant transformation due to advancements in drug formulation technologies, increasing demand for sustained and controlled-release medications, and the growing trend of outsourcing in the pharmaceutical industry. As GRDDS continues to gain traction, both the drug delivery system market and the outsourcing sector are evolving. Emerging trends such as increased focus on patient-centric formulations, technological innovation, and regulatory shifts are shaping the market landscape.

• Technological Innovations in GRDDS: Innovations in polymer-based systems, pH-sensitive materials, and gastric retention devices are enhancing the performance of GRDDS, making them more effective and patient-friendly.
• Patient-Centric Drug Delivery: There is a growing emphasis on developing GRDDS formulations that cater to individual patient needs, improving drug efficacy and minimizing side effects.
• Growth in Outsourcing Services: As pharmaceutical companies seek to reduce costs and enhance operational efficiency, outsourcing GRDDS manufacturing to specialized contract service providers has been on the rise.
• Focus on Long-Term Medication Adherence: GRDDS, designed for sustained release, is increasingly used for chronic conditions, promoting better adherence to treatment regimens.
• Regulatory Advancements: Evolving regulatory frameworks around the approval and quality control of GRDDS are driving innovation and ensuring greater consistency in the market.

The gastroretentive drug delivery system outsourcing market is set to grow significantly, driven by technological advancements, the increasing demand for patient-specific solutions, and the ongoing trend of outsourcing pharmaceutical manufacturing. Innovations in GRDDS technology, coupled with evolving regulations and a focus on medication adherence, will continue to shape the future of this market. Companies that can leverage these emerging trends will likely see substantial growth and enhanced market share.

Recent Developments in the Gastroretentive Drug Delivery System Outsourcing Market

The GRDDS outsourcing market has witnessed significant recent developments as pharmaceutical companies increasingly recognize the benefits of leveraging specialized contract manufacturers for gastro retentive drug formulations. These developments reflect both technological advancements and a broader trend toward cost-efficient drug development, production, and global market expansion. The market has become more competitive, with firms focusing on innovation and regulatory compliance to meet the needs of a rapidly growing patient base.

• Advances in GRDDS Technology: Recent breakthroughs in GRDDS, such as mucoadhesive systems and bio-adhesive polymers, have improved retention times and drug release control, enhancing therapeutic outcomes.
• Growing Demand for Outsourcing: Pharmaceutical companies are increasingly outsourcing GRDDS manufacturing to reduce production costs, mitigate risks, and shorten time-to-market for new drugs.
• Increase in Regulatory Compliance: Stricter regulatory standards, especially regarding safety and efficacy, are influencing how GRDDS formulations are developed and outsourced, leading to higher-quality systems.
• Expansion of Outsourcing Networks: Leading contract manufacturing organizations (CMOs) have expanded their services globally, catering to pharmaceutical companies looking to tap into emerging markets with robust GRDDS capabilities.
• Enhanced Drug Formulation Capabilities: Companies are enhancing their GRDDS formulations with next-generation technologies like controlled-release mechanisms and targeted delivery, which significantly improve treatment for chronic diseases.

Recent developments in the GRDDS outsourcing market highlight key trends such as technological advancements, increased regulatory scrutiny, and the growing preference for outsourcing as a cost-effective solution. Companies that can innovate and adapt to these changes while maintaining a focus on regulatory compliance and patient outcomes are likely to thrive in this dynamic and rapidly expanding market.

Strategic Growth Opportunities for Gastroretentive Drug Delivery System Outsourcing Market

The GRDDS outsourcing market presents substantial strategic growth opportunities as pharmaceutical companies increasingly focus on developing advanced drug delivery systems for chronic and complex diseases. The benefits of outsourcing, such as cost reduction, accelerated product development, and access to specialized expertise, create a favorable environment for market growth. By leveraging these opportunities, contract manufacturing organizations (CMOs) can expand their capabilities, enhance service offerings, and tap into new markets.

• Expansion of Outsourcing Partnerships: Pharmaceutical companies are increasingly partnering with CMOs that specialize in GRDDS to streamline production processes, improve efficiency, and access cutting-edge technologies.
• Growing Demand for Chronic Disease Management: The rise in chronic conditions such as diabetes, hypertension, and gastrointestinal disorders presents an opportunity to develop specialized GRDDS formulations aimed at improving long-term medication adherence.
• Geographic Expansion: Expanding outsourcing operations into emerging markets with growing healthcare needs can provide CMOs with a significant opportunity to gain market share in new regions.
• Personalized Medicine: The trend toward personalized and patient-specific formulations presents a significant opportunity for GRDDS companies to tailor solutions for individual therapeutic needs.
• Integration of Advanced Technologies: The integration of advanced technologies, such as AI and data analytics, in the GRDDS outsourcing process can optimize product development, reduce costs, and improve quality control.

Strategic growth opportunities in the GRDDS outsourcing market are abundant, driven by the demand for specialized drug delivery systems, advancements in chronic disease management, and the increasing need for personalized medicine. By focusing on expanding outsourcing partnerships, geographic reach, and integrating next-generation technologies, CMOs can capitalize on these opportunities. As the market grows, these factors will help shape the future of GRDDS outsourcing and create new avenues for growth.

Gastroretentive Drug Delivery System Outsourcing Market Driver and Challenges

The GRDDS outsourcing market is influenced by a variety of drivers, such as increasing demand for advanced drug delivery technologies, growing healthcare needs for chronic disease management, and the trend toward cost-efficient pharmaceutical manufacturing. However, the market also faces several challenges, including regulatory complexities, high production costs, and technological limitations. Understanding these drivers and challenges is essential for companies looking to navigate the competitive landscape and capitalize on growth opportunities.

Market Drivers:

• Rising Demand for Chronic Disease Treatments: The increasing prevalence of chronic diseases, such as diabetes and hypertension, drives the need for controlled and sustained drug release, creating demand for GRDDS.
• Outsourcing to Reduce Costs: Pharmaceutical companies are increasingly outsourcing GRDDS manufacturing to reduce production costs, enhance operational flexibility, and speed up time-to-market.
• Technological Advancements in Drug Formulation: Continuous improvements in drug delivery technologies, including bioadhesive systems and controlled-release mechanisms, support the growth of GRDDS applications.
• Focus on Medication Adherence: GRDDS plays a crucial role in improving patient adherence to long-term treatments, thereby driving its adoption in the management of chronic conditions.
• Regulatory Push for Safer, More Effective Therapies: Stricter regulatory requirements for drug delivery systems are driving innovation and enhancing the demand for reliable and compliant GRDDS solutions.

Market Challenges:

• High Development and Manufacturing Costs: The complexity of developing and producing GRDDS formulations can result in high initial investment and operational costs, especially for smaller companies.
• Regulatory Hurdles: Navigating complex and region-specific regulatory requirements can delay market entry and increase development costs.
• Technological Complexity: The need for advanced technologies to design and manufacture GRDDS requires specialized expertise, which may limit market participation for less experienced firms.

The GRDDS outsourcing market is driven by factors such as the increasing demand for chronic disease treatments, technological advancements, and the cost-saving benefits of outsourcing. However, it also faces challenges including high development costs, regulatory complexities, and technological barriers. By overcoming these challenges and leveraging market drivers, companies in the GRDDS outsourcing space can position themselves for sustained growth and success in a rapidly evolving market.

List of Gastroretentive Drug Delivery System Outsourcing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies gastroretentive drug delivery system outsourcing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the gastroretentive drug delivery system outsourcing companies profiled in this report include-

• F. Hoffmann La Roche
• Glaxo Smith Kline
• Lupin
• Pfizer
• Sun Pharma
• Ranbaxy
• Depomed

Gastroretentive Drug Delivery System Outsourcing by Segment

The study includes a forecast for the global gastroretentive drug delivery system outsourcing by type, dosage form, distribution channel, and region.

Gastroretentive Drug Delivery System Outsourcing Market by Type [Analysis by Value from 2018 to 2030]:

• High Density System
• Expandable Drug Delivery System
• Bioadhesive Drug Delivery System
• Floating Drug Delivery System
• Others

Gastroretentive Drug Delivery System Outsourcing Market by Dosage Form [Analysis by Value from 2018 to 2030]:

• Tablets
• Liquid
• Microspheres
• Capsule
• Others

Gastroretentive Drug Delivery System Outsourcing Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Gastroretentive Drug Delivery System Outsourcing Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Gastroretentive Drug Delivery System Outsourcing Market

Due to the growing need for sustained drug release formulations, the market for outsourcing Gastroretentive Drug Delivery Systems (GRDDS) is progressing significantly. This growth is driven by globalization as pharmaceutical companies enhance patient compliance and optimize therapeutic effectiveness. Outsourcing partners are focusing on innovative technologies and cost-efficient options. MRI's analysis indicates that significant in vitro and in vivo studies, as well as investments from the United States, China, Germany, India, and Japan, are helping develop market-specific novel gastroretentive formulations and manufacturing technologies.

• United States: In the U.S., the GRDDS outsourcing market is seeing an increased level of investment, particularly in offshoring GRDDS through Contract Development and Manufacturing Organizations (CDMOs). Companies are launching sophisticated formulations aimed at improving bioavailability and sustaining the rate of drug release. Collaborating with CDMOs has become a source of innovation for pharmaceutical companies, leading to the development of new types of gastroretentive systems, such as floating tablets and hydrogels, which enhance patient compliance.
• China: The GRDDS market in China is growing rapidly due to the expanding capacity of the domestic pharmaceutical industry and the rising demand for advanced drug delivery strategies. Research projects are being supported by the government, and local companies are taking the initiative to develop the next generation of vertical and lateral GRDDS systems. Domestic and foreign firms are collaborating to improve formulation methods and ensure regulatory compliance.
• Germany: Germany is well-known for its pharmaceutical development and technological advancements, and this is also evident in its GRDDS outsourcing market. Recent trends include the development of individualized therapies and focused drug delivery systems. German CDMOs are increasingly using 3D printing technology to design specific gastroretentive formulations tailored to individual patients.
• India: In India, the GRDDS outsourcing market is expanding as local pharmaceutical companies become more open to innovative approaches in drug delivery. The focus on providing cost-effective healthcare has led to the growth of more affordable GRDDS products. International partnerships are helping Indian companies acquire new competencies, enabling them to establish a global presence.
• Japan: From a regulatory standpoint, Japan's GRDDS outsourcing market is sustained by a strong focus on quality and innovation. Japanese pharmaceutical companies are investing in next-generation formulation technologies and collaborating with research institutes to develop advanced gastroretentive systems. Another emerging trend is the increasing regulatory encouragement for innovative drug delivery products, which is helping bring new products to market more rapidly.

Features of the Global Gastroretentive Drug Delivery System Outsourcing Market

Market Size Estimates: Gastroretentive drug delivery system outsourcing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Gastroretentive drug delivery system outsourcing market size by type, dosage form, distribution channel, and region in terms of value ($B).

Regional Analysis: Gastroretentive drug delivery system outsourcing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, dosage form, distribution channel, and regions for the gastroretentive drug delivery system outsourcing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the gastroretentive drug delivery system outsourcing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the gastroretentive drug delivery system outsourcing market by type (high density system, expandable drug delivery system, bioadhesive drug delivery system, floating drug delivery system, and others), dosage form (tablets, liquid, microspheres, capsule, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Gastroretentive Drug Delivery System Outsourcing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Gastroretentive Drug Delivery System Outsourcing Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Gastroretentive Drug Delivery System Outsourcing Market by Type
  • 3.3.1: High Density System
  • 3.3.2: Expandable Drug Delivery System
  • 3.3.3: Bioadhesive Drug Delivery System
  • 3.3.4: Floating Drug Delivery System
  • 3.3.5: Others
• 3.4: Global Gastroretentive Drug Delivery System Outsourcing Market by Dosage Form
  • 3.4.1: Tablets
  • 3.4.2: Liquid
  • 3.4.3: Microspheres
  • 3.4.4: Capsule
  • 3.4.5: Others
• 3.5: Global Gastroretentive Drug Delivery System Outsourcing Market by Distribution Channel
  • 3.5.1: Hospital Pharmacies
  • 3.5.2: Retail Pharmacies
  • 3.5.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Gastroretentive Drug Delivery System Outsourcing Market by Region
• 4.2: North American Gastroretentive Drug Delivery System Outsourcing Market
  • 4.2.1: North American Market by Type: High Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, and Others
  • 4.2.2: North American Market by Dosage Form: Tablets, Liquid, Microspheres, Capsule, and Others
• 4.3: European Gastroretentive Drug Delivery System Outsourcing Market
  • 4.3.1: European Market by Type: High Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, and Others
  • 4.3.2: European Market by Dosage Form: Tablets, Liquid, Microspheres, Capsule, and Others
• 4.4: APAC Gastroretentive Drug Delivery System Outsourcing Market
  • 4.4.1: APAC Market by Type: High Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, and Others
  • 4.4.2: APAC Market by Dosage Form: Tablets, Liquid, Microspheres, Capsule, and Others
• 4.5: ROW Gastroretentive Drug Delivery System Outsourcing Market
  • 4.5.1: ROW Market by Type: High Density System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, Floating Drug Delivery System, and Others
  • 4.5.2: ROW Market by Dosage Form: Tablets, Liquid, Microspheres, Capsule, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Gastroretentive Drug Delivery System Outsourcing Market by Type
  • 6.1.2: Growth Opportunities for the Global Gastroretentive Drug Delivery System Outsourcing Market by Dosage Form
  • 6.1.3: Growth Opportunities for the Global Gastroretentive Drug Delivery System Outsourcing Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Gastroretentive Drug Delivery System Outsourcing Market by Region
• 6.2: Emerging Trends in the Global Gastroretentive Drug Delivery System Outsourcing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Gastroretentive Drug Delivery System Outsourcing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Gastroretentive Drug Delivery System Outsourcing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: F. Hoffmann La Roche
• 7.2: Glaxo Smith Kline
• 7.3: Lupin
• 7.4: Pfizer
• 7.5: Sun Pharma
• 7.6: Ranbaxy
• 7.7: Depomed